Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2016

Press Releases from the ESMO 2016 Congress

Best of ESMO 2016 Congress

ESMO 2016 Congress has broken records, not only of attendance, but in terms of the quality science being presented, that will impact the practice of oncology

Epidemiology/Etiology/Cancer Prevention

Improving Cancer Screening Participation Should be a Priority

Early diagnosis of cancer is linked to better survival rates. Unfortunately, participation rates for cancer screening worldwide are low even when screening programmes are free. ESMO 2016 is showcasing five studies on this important area of cancer management which look at alternative ways to overcome barriers and improve screening rates.

Gynaecologic malignancies

Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM). The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.

Impact of Cognitive Functions on Oral Cancer Therapies

The development of oral cancer drugs as a modality therapy over the last decade has highlighted the problem of non-adherence. Only cancer drugs that are taken can actually work. Contrary to what is expected, a significant share of cancer patients doesn’t take their cancer drugs as prescribed.

Breast cancer;  Anticancer agents & Biologic therapy

Ribociclib Improves Progression-free Survival in Advanced Breast Cancer

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.

Translational research

Single-Arm Trials Improve Early Access to Rare Cancer Drugs

Although randomised clinical trials (RCTs) remain the gold standard for evaluating the benefit/risk of cancer drugs, single-arm trials (SATs) can provide invaluable opportunities to speed up cancer drug development and approval

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.